Oncology Nursing News
Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management ...
CIPN Experienced by Many Patients Years After Treatment
Sep 22, 2017 · Ninety percent of patients with cancer may experience chemotherapy-induced peripheral neuropathy (CIPN) during treatment, and many will see this adverse effect long after treatment ends.
Low-Level Light Therapy Shows Promise for Hair Regrowth After …
Apr 27, 2017 · Nurses know that for their patients undergoing chemotherapy, hair loss is one of their most feared side effects. Although recent interventions involve cooling systems worn on the scalp to reduce alopecia during chemotherapy, there may now be a new option to improve hair recovery after the fact.
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
Nov 5, 2024 · SHR-A1921, a novel antibody-drug conjugate (ADC) demonstrated activity and safety for the treatment of patients with platinum-resistant ovarian cancer, according to data from a first-in-human phase 1 study (NCT05154604) that were presented during the 2024 ESMO Congress. 1 Evaluable patients treated with SHR-A1921 at a dose of 3.0 mg/kg once every 3 weeks (n = 26) experienced an overall ...
Daratumumab Monotherapy Shows Survival Benefit in Smoldering …
Dec 9, 2024 · Compared with active monitoring, subcutaneous daratumumab (Darzalex Faspro) led to significant progression-free survival (PFS) benefit in patients with intermediate- or high-risk smoldering multiple myeloma, according to primary results from the phase 3 AQUILA study (NCT03301220). 1-2 Further, the greatest PFS benefit was …
CDCT1 Testing Study Highlights Pitfalls in Current NCCN Genetic ...
Apr 18, 2023 · Whole exome sequencing testing identified genetic conditions in individuals who ordinarily would not have met current National Comprehensive Cancer Network (NCCN) guidelines for testing, according to data presented during the 2023 AACR Annual Meeting.
Oncology Nurse Staffing Is Variable and Multifactorial
Jul 19, 2012 · Nurse staffing varies from institution to institution, depending on many factors, both internal and external. To gain a better understanding of nurse staffing, ratios of nurses to patients, and productivity, a survey was sent to ONS members.
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast …
Oct 24, 2024 · The American Society of Clinical Oncology (ASCO) recently announced guidelines outlining a preference for abemaciclib (Verzenio) over ribociclib (Kisqali) for the treatment of patients with node-positive, high-risk, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 1. The recommendation is based on findings from the monarchE (NCT03155997 ...
Acalabrutinib-Venetoclax Reduces Risk for Progression in Frontline …
Dec 9, 2024 · At a median follow-up of 40.8 months, the median progression-free survival (PFS) was not reached by blinded independent central review (BICR) with acalabrutinib plus venetoclax (AV) and acalabrutinib plus venetoclax and obinutuzumab (AVO) arms and was 47.6 months with investigator’s choice of fludarabine plus cyclophosphamide and rituximab (Rituxan; FCR) or bendamustine plus rituximab (BR).
Adding Chemo to Osimertinib Improves Survival After Progression …
Apr 5, 2024 · Patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) treated with firstline osimertinib (Tagrisso) plus platinum-pemetrexed chemotherapy demonstrated long-term, clinically meaningful, and statistically significant survival outcomes after disease progression compared with osimertinib alone, according to a prespecified analysis of post-progression outcomes and updated ...